血清microRNA-760-3p和血管内皮钙黏蛋白预测冠心病患者抗血小板治疗的出血风险  

Serum miR-760-3p and VE-cadherin predict bleeding risk in patients with coronary heart disease treated with antiplatelet therapy

作　　者：关欣 杨平[2] 柳江海 GUAN Xin;YANG Ping;LIU Jianghai(Department of Cardiology,Xi'an Trade Union Hospital,Xi'an,710100,China;Baoji People's Hospital;Cardiovascular Hospital Affiliated to Xiamen University)

机构地区：[1]西安工会医院心血管内二科,西安710100 [2]宝鸡市人民医院 [3]厦门大学附属心血管病医院

出　　处：《临床心血管病杂志》2025年第2期110-114,共5页Journal of Clinical Cardiology

摘　　要：目的:探讨血清microRNA(miR)-760-3p和血管内皮钙黏蛋白(VE-cadherin)水平预测冠心病(CHD)患者抗血小板治疗出血风险的价值。方法:本研究纳入了214例于2021年1月—2023年8月接受抗血小板治疗的CHD患者。根据随访期间是否发生出血事件,将患者分为出血组(33例)和非出血组(181例)。通过qRT-PCR、ELISA检测两组患者的血清miR-760-3p和VE-cadherin水平,比较两组间的差异。使用logistic回归分析评估miR-760-3p和VE-cadherin水平与出血事件之间的关系,并通过ROC曲线分析其预测能力。结果:在214例患者中,出血事件发生率为15.42%。出血组的miR-760-3p和VE-cadherin水平显著高于非出血组(P<0.05)。Logistic回归分析显示,miR-760-3p(OR=2.231,95%CI 1.254~4.002)和VE-cadherin(OR=1.570,95%CI 1.043~2.363)水平是出血事件发生的影响因素(P<0.05)。ROC曲线显示,血清miR-760-3p和VE-cadherin联合预测CHD患者抗血小板治疗出血风险的AUC为0.823,较两指标单独预测的价值高(P<0.05)。结论:高表达的miR-760-3p和VE-cadherin与出血风险显著相关,其联合检测有助于预测CHD抗血小板治疗后出血风险。Objective To explore the value of serum miR-760-3p and vascular endothelial cadherin(VE-cadherin)levels in predicting the bleeding risk of patients with coronary heart disease(CHD)treated with antiplatelet therapy.Methods This study included 214 CHD patients who received antiplatelet therapy from January 2021 to August 2023.According to whether bleeding events occurred during follow-up,patients were divided into bleeding group(33 cases)and non-bleeding group(181 cases).The serum levels of miR-760-3p and VE-cadherin in the two groups of patients were detected by qRT-PCR and ELISA,and the differences between the two groups were compared.Logistic regression analysis was used to evaluate the relationship between miR-760-3p and VE-cadherin levels and the incidence of bleeding events,and their predictive ability was analyzed by ROC curve.Results Among 214 patients,the incidence rate of bleeding events was 15.42%.qRT-PCR and ELISA test results showed that the levels of miR-760-3p and VE-cadherin in the bleeding group were significantly lower than those in the non-bleeding group(P<0.05).Logistic regression analysis showed that the levels of miR-760-3p and VE-cadherin were significantly related to the occurrence of bleeding events(P<0.05).The OR of miR-760-3p was 2.231(95%CI:1.254-4.002),and the OR of VE-cadherin was 1.570(95%CI:1.043-2.363).The ROC curve showed that the AUC of serum miR-760-3p and VE-cadherin in predicting the bleeding risk of antiplatelet therapy in CHD patients was 0.823,which was higher than that predicted by the two indicators alone(P<0.05),indicating that the combination of the two had better predictive power.Conclusion Serum miR-760-3p and VE-cadherin levels can be used as potential biomarkers to predict the risk of bleeding during antiplatelet therapy in patients with CHD.High expression of miR-760-3p and VE-cadherin are significantly associated with bleeding risk.

关 键 词：microRNA-760-3p 血管内皮钙黏蛋白 抗血小板 出血风险 

分 类 号：R541.4[医药卫生—心血管疾病]